Biomea Fusion to release Phase I results for oral GLP-1 agonist BMF-650 on Oct. 13
BMEA•Biomea Fusion scheduled a presentation of Phase I results for its oral small-molecule GLP-1 receptor agonist BMF-650 on Oct. 13, 2026. The announcement disclosed no trial outcomes.
1. Results scheduled
Biomea Fusion said it will present Phase I results for BMF-650, an oral small-molecule GLP-1 receptor agonist, on Oct. 13, 2026, in a conference call and webcast. The announcement disclosed no trial outcomes.
